ONCT
Oncternal Therapeutics Inc

9,232
Loading...
Loading...
News
all
press releases
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Globe Newswire·1y ago
News Placeholder
More News
News Placeholder
Oncternal Therapeutics (NASDAQ:ONCT) Upgraded by StockNews.com to "Hold"
StockNews.com upgraded shares of Oncternal Therapeutics (NASDAQ:ONCT Free Report) from a sell rating to a hold rating in a research report released on Friday morning. A number of other...
Zolmax·1y ago
News Placeholder
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Joint (JYNT Research Report), Xtant Medical Holdings...
TipRanks Financial Blog·1y ago
News Placeholder
Oncternal Therapeutics reports Q4 EPS ($3.11), consensus (3.07)
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Third dosing cohort fully enrolled for our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to...
Globe Newswire·1y ago
News Placeholder
Panorama des b n fices de Oncternal Therapeutics
Oncternal Therapeutics (NASDAQ:ONCT) publiera ses derniers b n fices ce jeudi, 7 mars. Pour en savoir plus ce sujet, veuillez consulter ce guide aux b n fices du quatri me trimestre publi s...
Benzinga·2y ago
News Placeholder
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Globe Newswire·2y ago
News Placeholder
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Globe Newswire·2y ago
News Placeholder
Oncternal Therapeutics reports inducement award under Nasdaq listing rule
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Globe Newswire·2y ago

Latest ONCT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.